FrancophonIA/ELRC3.0 huggingface dataset:
English: Treatment with Hepsera should be started by a doctor who has experience in the management of chronic hepatitis B. The recommended dose is 10 mg once a day.
Maltese: It-trattament b'Hepsera għandu jinbeda minn tabib li jkollu esperjenza fil-ġestjoni tal-epatite B kronika.
English: For more information, see the summary of product characteristics (also part of the EPAR).
Maltese: Għal iżjed informazzjoni, ara s-sommarju tal-karatteristiċi tal-prodott (parti wkoll mill-EPAR).
English: Representative of Intervet in the Slovak Rep.
Maltese: Is-Slovakja Representative of Intervet in the Slovak Rep.
English: Belgium Intervet Belgium Bedrijvenlaan 7
Maltese: Intervet Belgium Bedrijvenlaan 7
English: One dose = 2 ml
Maltese: Doża waħda = 2 ml
English: Intervet Danmark AS PO Box 66
Maltese: Id-Danimarka Intervet Danmark AS PO Box 66
English: 50 ELISA units, inducing ≥ 4.6 log2 VN units
Maltese: 50 unitajiet ELISA, li tagħti ≥ 4.6 log2 VN unità
English: Intervet Portuguesa Ltd. Estrada Nacional 249, Km 14,2 PT-2725-397 Mem Martins Codes
Maltese: Estrada Nacional 249, Km 14,2 PT-2725-397 Mem Martins Codes
English: Intervet International Podruznica
Maltese: Is-Slovenja Intervet International Podruznica
English: Intervet Ireland Ltd. Magna Drive Magna Business Park Citywest Road IR-Dublin 24
Maltese: Magna Drive Magna Business Park Citywest Road IR-Dublin 24
English: Intervet International B.V. Wim de Korverstraat 35 NL-5831 AN Boxmeer The Netherlands Tel: + 31 485 587 652
Maltese: Wim de Korverstraat 35 NL-5831 AN Boxmeer The Netherlands Tel: + 31 485 587 652
English: CY-1665 Nicosia Cyprus
Maltese: CY-1665
English: In March 2006 Intervet then submitted an application for a marketing authorisation for this vaccine following a repeat use mutual recognition procedure, with Germany acting as Reference Member State, for Denmark, Poland, Slovakia and Slovenia.
Maltese: F'Marzu ta' l-2006, Intervet issottomettew applikazzjoni għall-awtorizzazzjoni għat-tqegħid fis-suq ta' din it-tilqima wara proċedura ta' rikonoxximent reċiproku għal użu ripetut, bil-Ġermanja taġixxi bħala Stat Membru ta' Referenza, għad-Danimarka, għall-Polonja, għas-Slovakja u għas-Slovenja.
English: Intervet Bulgaria EOOD 7, Iskarsko shoes blvd BG-1528 Sofia Bulgaria
Maltese: Il-Bulgarija Intervet Bulgaria EOOD 7, Iskarsko shoes blvd
English: Czech Republic
Maltese: Slovak Republic
English: 7.e.13 Hungary
Maltese: HU-Boráros tér. 7/2. 7.e.13 Hungary
English: The CVMP has concluded that the risk/benefit for Bovilis BVD is favourable.
Maltese: Is-CVMP ikkonkluda li r-riskju/benefiċċju għal Bovilis BVD huwa wieħed favorevoli.
English: DK-2740 Skovlunde Denmark
Maltese: DK-2740
English: During its meeting of November 2006, the CVMP started a referral procedure under Article 33(4) of Directive 2001/82/EC as amended for Bovilis BVD.
Maltese: Matul il-laqgħa tiegħu ta' Novembru ta' l-2006, is-CVMP beda proċedura ta' riferiment skond lArtikolu 33(4) tad-Direttiva 2001/82/KE kif emendata għal Bovilis BVD.
English: Czech Republic Tel: +420 (2) 333 440 25 Fax: +420 (2) 333 440 22
Maltese: Czech Republic Tel: +420 (2) 333 440 25
English: • extraneous agents testing of finished batches of Bovilis BVD for FMDV, BLV, BTV and IBRV is not required in the relevant monographs
Maltese: • l-ittestjar ta' gruppi lesti ta' tilqimiet ta' Bovilis BVD għall-aġenti barranin FMDV, BLV, BTV u IBRV mhux meqjus meħtieġ skond il-monografi relevanti
English: Denmark
Maltese: Skovlunde Denmark
English: The matter was referred to the Co-ordination Group for Mutual Recognition and Decentralised Procedures, CMD(v), for a 60 day procedure in accordance with Article 33(1) of Directive 2001/82/EC, as amended.
Maltese: Il-materja ġiet riferuta lill-Grupp ta' Ko-ordinazzjoni għar-Rikonoxximent Reċiproku u l-Proċeduri Deċentralizzati, is-CMD(v), għal perjodu ta' 60 jum skond l-Artikolu 33(1) tad-Direttiva 2001/82/KE, kif emendata.
English: The application was made in accordance with Article 12.3 of Directive 2001/82/EC as a stand alone application.
Maltese: Lapplikazzjoni saret skond l-Artikolu 12.3 tad-Direttiva 2001/82/KE bħala applikazzjoni għaliha.
English: As the likelihood of contamination of Bovilis BVD vaccine, and the subsequent probability of seroconversion by such contaminants is extremely low, the advantage of additional final product testing for extraneous agents (serological method) is considered to be negligible.
Maltese: Billi l-probabilità ta' kontaminazzjoni tat-tilqima ta' Bovilis BVD, u l-probabilità sussegwenti ta' serokonverżjoni b'kontaminanti bħal dawn hija estremament baxxa, il-vantaġġ ta' provi addizzjonali tal-prodott finali għal aġenti barranin (bil-metodu seroloġiku) huwa kkunsidrat wieħed negleġibbli.
English: Bovilis BVD was first authorised in Germany on 6 May 1998 (as Bovilis BVD-MD).
Maltese: Bovilis BVD kien awtorizzat għall-ewwel darba fil-Ġermanja fis-6 ta' Mejju 1998 (bħala Bovilis BVD-MD).
English: Per 2 ml dose:
Maltese: Għal kull doża ta' 2 ml:
English: Cyprus
Maltese: Nicosia Cyprus
English: Cattle Intramuscular injection.
Maltese: Injezzjoni għal ġolmuskoli.
English: The production and testing of Bovilis BVD vaccine are in accordance with the relevant requirements of Directive 2001/82/EC, the relevant EU guidelines and the relevant monographs of the Ph.Eur.
Maltese: Il-produzzjoni u l-prova tat-tilqima ta' Bovilis BVD huma skond il-ħtiġijiet relevanti tad-Direttiva 2001/82/KE, il-linji gwida relevanti ta' l-UE u l-monografi relevanti tal-Ph.Eur.
English: The risk of accidental contamination with FMDV, IBRV, BLV and BTV is concluded to be low; consequently the risk of seroconversion against the listed agents is also concluded to be low.
Maltese: Ir-riskji ta' kontaminazzjoni aċċidentali b'FMDV, IBRV, BLV u BTV huma baxxi; konsegwentament ir-riskju tas-serokonverżjoni kontra s-sustanzi elenkati huwa meqjus baxx ukoll.
English: Member State Applicant or Marketing Authorisation Holder
Maltese: Stat Membru Applikant jew Detentur ta' lAwtorizzazzjoni għat-Tqegħid fis-Suq
English: Denmark considers that the proposed testing regime to demonstrate freedom from extraneous agents is insufficient to ensure that Bovilis BVD would not interfere with their national eradication campaigns for certain animal diseases and that therefore the benefit: risk assessment for Bovilis BVD is negative and authorisation of the product would represent a potential serious risk to animal health.
Maltese: Id-Danimarka tqis li l-metodu propost għall-ittestjar biex juri l-ħelsien minn aġenti barranin ma jistax jiżgura li Bovilis BVD m'hiex se tinterferixxi mal-kampanji nazzjonali tagħhom għall-eradikazzjoni ta' ċerti mardiet ta' l-annimali u li għalhekk, il-valutazzjoni tar-relazzjoni bejn il-benefiċċju u r-riskju għal Bovilis BVD hi waħda negattiva u li l-awtorizzazzjoni tal-prodott tirrappreżenta riskju potenzjali serju għas-saħħa ta' l-annimali.
English: At day 90 of the MRP, 2 August 2006, Denmark could not agree to the granting of a marketing authorization as they considered the product to present a potential serious risk for animal health.
Maltese: Fid-disgħin jum tal-MRP, fit-2 ta' Awwissu 2006, id-Danimarka ma setgħetx taqbel ma' l-għoti ta' awtorizzazzjoni għat-tqegħid fis-suq għax ħassetw li l-prodott kien jippreżenta riskju potenzjali serju għas-saħħa ta' l-annimali.
English: Strength
Maltese: Frat
English: Pursuant to Article 33(4) of Council Directive 2001/82/EC, as amended, the matter has been referred to CVMP.
Maltese: Kif preskritt fl-Artikolu 33(4) tad-Direttiva tal-Kunsill 2001/82/KE, kif emendata, il-materja ġiet riferuta lis-CVPM.
English: • the production of Bovilis BVD vaccine is in compliance with GMP requirements
Maltese: • Il-produzzjoni tat-tilqima ta' Bovilis BVD hi konformi mal-ħtiġiet tal-GMP
English: No scientific arguments are available concerning how the additional testing would minimise the risk of possible seroconversion induced by the vaccine.
Maltese: L-ebda argumenti xjentifiċi magħrufa ma juru kif il-provi addizzjonali jistgħu jnaqqsu r-riskju ta' serokonverżjoni possibbli li jirriżulta mill-vaċċin.
English: The initial mutual recognition procedure was finalised on 24 June 1999, and 11 other Member States authorised the product at this time.
Maltese: Il-proċedura inizjali ta' għarfien reċiproku ntemmet fl-24 ta' Ġunju 1999, u 11-il Stat Membru ieħor awtorizzaw il-prodott f'dan iż-żmien.
English: Consequently Germany notified the EMEA, on 31 October 2006, that the CMD(v) failed to reach an agreement regarding Bovilis BVD.
Maltese: Konsegwentament il-Ġermanja għarrfet lill-EMEA, fil-31 ta' Ottubru 2006, li s-CMD(v) naqas milli jilħaq ftehim dwar Bovilis BVD.
English: In general, the absence of extraneous agents in vaccines can be ensured by: GMP compliance of the production system Extraneous agents testing of raw materials Extraneous agents testing of batches of finished product, if required.
Maltese: B'mod ġenerali, in-nuqqas ta' aġenti barranin fit-tilqimiet jista' jiġi żgurat b': konformità tal-GMP tas-sistema tal-produzzjoni l-ittestjar tal-materja prima għal aġenti barranin l-ittestjar ta' gruppi ta' prodotti lesti għal aġenti barranin, jekk dan ikun meħtieġ.
English: The benefits of Bovilis BVD vaccine are accepted.
Maltese: Il-benefiċċji ta' Bovilis BVD huma aċċettati.
English: SK-040 01 Kosice Slovak Republic Tel: +421 (55) 676 9405 Fax: +421 (55) 676 9873
Maltese: Fax: +421 (55) 676 9873
English: It is worthy of note that the first EU marketing authorisation for Bovilis BVD was granted in 1998, and the vaccine is currently authorised in 14 EU Member States.
Maltese: Ta' min isemmi li l-ewwel awtorizzazzjoni għat-tqegħid fis-suq ta' l-UE għal Bovilis BVD ingħatat fl1998, u t-tilqima bħalissa hija awtorizzata f'14-il Stat Membru ta' l-UE.
English: Therefore the requested additional specified extraneous testing requirement is scientifically not justified for Bovilis BVD.
Maltese: Għalhekk it-talba għal provi addizzjonali għal aġenti barranin speċifikati mhijiex xjentifikament ġustifikata għal Bovilis BVD.
English: Based on the current requirements and the relevant safeguards (e.g., GMP) the CVMP concludes that the Applicant has taken adequate measures to guarantee the quality and safety of Bovilis BVD.
Maltese: Skond il-ħtiġiet attwali u s-salvagwardji relevanti (eż. GMP), is-CVMP ikkonkluda li l-Applikant irid ikun ħa l-miżuri adegwati biex jiggarantixxi l-kwalità tas-sigurtà ta' Bovilis BVD.
English: The procedure started on 13 March
Maltese: Ilproċedura bdiet fit-13 ta' Marzu 2006.
English: Although the consequences of an accidental seroconversion against the listed extraneous agents would damage the animal health status of a country free from the four specified diseases, the benefit: risk evaluation remains positive due to the low risk of contamination of the product.
Maltese: Dejjem jibqa' riskju żgħir ta' kontaminazzjoni minn sustanza barranija minn varjetà ta' sorsi.
English: Animal species
Maltese: FIL-PAKKETT
English: It is available as tablets (20 mg; 40 and 80 mg).
Maltese: Jiġi f'pilloli (20 mg; 40 mg u 80 mg).
English: Other information about Telmisartan Actavis:
Maltese: Informazzjoni oħra dwar Telmisartan Actavis:
English: Telmisartan Actavis is a ‘generic medicine'.
Maltese: Telmisartan Actavis hija ‘mediċina ġenerika'.
English: The full EPAR for Telmisartan Actavis can be found on the Agency's website EMA website/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: L-EPAR sħiħ għal Telmisartan Actavis jista' jinstab fis-sit elettroniku tal-Aġenzija taħt is-sit web tal- EMA website/Find medicine/Human medicines/European Public Assessment Reports.
English: This is a summary of the European public assessment report (EPAR) for Telmisartan Actavis.
Maltese: Dan id-dokument huwa sommarju tar-Rapport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Telmisartan Actavis.
English: For the treatment of essential hypertension, the usual recommended dose of Telmisartan Actavis is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Maltese: Għall-kura tal-ipertensjoni essenzjali, normalment id-doża rakkomandata ta' Telmisartan Actavis hija 40 mg darba kuljum, iżda xi pazjenti jistgħu jibbenefikaw mill-użu ta' doża ta' 20 mg darba kuljum.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Telmisartan Actavis on 30 September 2010.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Telmisartan Actavis fit-30 ta' Settembru 2010.
English: Telmisartan Actavis is a medicine that contains the active substance telmisartan.
Maltese: Telmisartan Actavis hija mediċina li fiha s-sustanza attiva telmisartan.
English: The active substance in Telmisartan Actavis, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Maltese: Is-sustanza attiva f'Telmisartan Actavis, it-telmisartan, hija 'antagonista ta' riċettur ta' anġjotensin II', li jfisser li timblokka l-azzjoni ta' ormon fil-ġisem imsejjaħ anġjotensin II. Anġjotensin II huwa vażokostrittur qawwi (sustanza li traqqaq il-vini tad-demm).
English: Because Telmisartan Actavis is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Micardis.
Maltese: Minħabba li Telmisartan Actavis hija mediċina ġenerika, studji fuq persuni ġew limitati għal testijiet li jiddeterminaw dak li huwa bijoekwivalenti għall-mediċina ta' referenza, Micardis.
English: pressure is not reached, the dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Maltese: Jekk il-pressjoni tad-demm fil-mira ma tintlaħaqx, id-doża tista' tiżdied għal 80 mg, jew tista' tiżdied mediċina oħra għall-pressjoni għolja, bħal hydrochlorothiazide.
English: The CHMP concluded that, in accordance with EU requirements, Telmisartan Actavis has been shown to have comparable quality and to be bioequivalent to Micardis.
Maltese: Is-CHMP ikkonkluda li, skont ir-rekwiżiti tal-UE, Telmisartan Actavis intwera li għandu kwalità komparabbli u li huwa bijoekwivalenti għal Micardis.
English: This means that Telmisartan Actavis is similar to a ‘reference medicine' already authorised in the European Union (EU) called Micardis.
Maltese: Dan ifisser li Telmisartan Actavis huwa simili għal ‘mediċina ta' referenza' li diġà hija awtorizzata fl-Unjoni Ewropea (UE) msejħa Micardis.
English: What is Telmisartan Actavis?
Maltese: Kif jintuża Telmisartan Actavis?
English: It also allows the heart to pump blood more easily, which can help to reduce the risk of future cardiovascular problems.
Maltese: Jippermetti wkoll lillqalb sabiex tippompja d-demm aktar faċilment, li jista' jgħin sabiex jitnaqqas ir-riskju ta' problemi kardjovaskulari futuri.
English: What are the benefits and risks of Telmisartan Actavis?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Telmisartan Actavis?
English: Why has Telmisartan Actavis been approved?
Maltese: Għaliex ġie approvat Telmisartan Actavis?
English: Telmisartan Actavis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Maltese: Telmisartan Actavis jintuża wkoll biex jipprevjeni problemi kardjovaskulari (problemi bil-qalb u bil-vini tad-demm) bħal attakki tal-qalb jew puplesiji.
English: Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Maltese: Il-pazjenti li jbatu minn indeboliment serju fil-kliewi għandhom jingħataw doża aktar baxxa ta' 20 mg darba kuljum.
English: By blocking the receptors to which angiotensin II normally attaches, telmisartan stops the hormone having an effect, allowing the blood vessels to widen.
Maltese: Billi jimblokka r-riċetturi li magħhom normalment jeħel l-anġjotensin II, telmisartan iwaqqaf lill-ormon milli jkollu effett, u dan jippermetti lillvini tad-demm sabiex jitwessgħu.
English: This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke.
Maltese: Dan jippermetti lill-pressjoni tad-demm tinżel, u b'hekk inaqqas irriskji assoċjati ma' pressjoni tad-demm għolja, bħal attakk tal-qalb jew puplesija.
English: Because Telmisartan Actavis is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Telmisartan Actavis hija mediċina ġenerika u hija bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tagħha huma kkunsidrati li huma l-istess bħal tal-mediċina ta' referenza.
English: How has Telmisartan Actavis been studied?
Maltese: Kif ġie studjat Telmisartan Actavis?
English: How does Telmisartan Actavis work?
Maltese: X'inhu Telmisartan Actavis?
English: The full EPAR for the reference medicine can also be found on the Agency's website.
Maltese: L-EPAR sħiħ għall-mediċina ta' referenza jinstab fis-sit web tal-Aġenzija.
English: MA (EU) Number (Invented) name Strength Pharmaceutical Form Route of Administration
Maltese: Numru tal-MA (EU) Isem (inventat)
English: 0.6 ml (10 mg/ml) 1 pre-filled syringe
Maltese: 0.6 mL (10 mg/mL) Siringa mimlija għal-lest
English: Innovax-ND-IBD received a marketing authorisation valid throughout the EU on 22 August 2017.
Maltese: Innovax-ND-IBD ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fit-22 ta' Awwissu 2017.
English: The full EPAR for Innovax-ND-IBD can be found on the Agency's website: ema.europa.eu/medicines/veterinary/EPAR/innovax-nd-ibd.
Maltese: ema.europa.eu/medicines/veterinary/EPAR/innovax-nd-ibd.
English: For MD, 87% of the vaccinated chickens were protected against challenge at 9 days after vaccination.
Maltese: Għal MD, 87 % tat-tiġieġ imlaqqma ġew protetti kontra sfida 9 ijiem wara t-tilqim.
English: This overview was last updated in March 2019.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar f'Marzu 2019.
English: Innovax-ND-IBD is a veterinary vaccine used to protect chickens against Newcastle disease (ND), infectious bursal disease (IBD) and Marek's disease (MD).
Maltese: Innovax-ND-IBD huwa vaċċin veterinarju li jintuża għall-protezzjoni tat-tiġieġ kontra l-marda ta' Newcastle (ND, Newcastle disease), il-marda infettiva bursal (IBD, infectious bursal disease) u l-marda ta' Marek (MD, Marek's disease).
English: Other information about Innovax-ND-IBD
Maltese: Informazzjoni oħra dwar Innovax-ND-IBD
English: For IBD, 100% of vaccinated chickens did not develop IBD when challenged at 46 days after vaccination.
Maltese: Għal IBD, 100 % tat-tiġieġ imlaqqma ma żviluppawx IBD meta sfidati fis-46 jum wara t-tilqim.
English: Vaccinated birds had a protection level of between 81% and 95% against disease signs.
Maltese: L-għasafar imlaqqma kellhom livell ta' protezzjoni ta' bejn 81 % u 95 % kontra s-sinjali tal-marda.
English: For ND, 60% of vaccinated chickens did not develop ND when challenged at 4 weeks after vaccination and 95% of vaccinated chickens were protected 6 weeks after vaccination.
Maltese: Għal ND, 60 % tat-tiġieġ imlaqqma ma żviluppawx ND meta ġew sfidati 4 ġimgħat wara t-tilqim u 95 % tat-tiġieġ imlaqqma ġew protetti 6 ġimgħat wara t-tilqim.
English: Innovax-ND-IBD contains a live modified strain of turkey herpesvirus called strain HVP360.
Maltese: Innovax-ND-IBD fih razza modifikata ħajja tal-virus ħerpes tad-dundjan li tissejjaħ razza HVP360.
English: For ND, 92% of chickens from vaccinated eggs did not develop ND when challenged at 46 days after vaccination.
Maltese: Għal ND, 92 % tat-tiġieġ li ġew minn bajd imlaqqam ma żviluppawx ND meta sfidati fis-46 jum wara t-tilqim.
English: Protection against ND starts 4 weeks after vaccination and lasts 8 weeks.
Maltese: Il-protezzjoni kontra ND tibda 4 ġimgħat wara t-tilqim u ddum 8 ġimgħat.
English: For MD, 91% of chickens from vaccinated eggs did not develop MD when challenged at 8 days of age.
Maltese: Għal MD, 91 % tat-tiġieġ imlaqqma ma żviluppawx MD meta ġew sfidati fl-età ta' tmint ijiem.
English: In the future if the animals are exposed to similar proteins the immune system will be able to respond more quickly.
Maltese: Jekk fil-futur l-annimali jiġu esposti għal proteini simili, is-sistema immunitarja se tkun kapaċi tirreaġixxi aktar malajr.
English: The turkey herpesvirus strain HVP360 has been modified so that it will produce proteins from ND virus and IBD virus.
Maltese: Ir-razza HVP360 tal-virus ħerpes tad-dundjan ġiet modifikata sabiex din tipproduċi proteini mill-virus ND u l-virus IBD.
English: IBD, also known as Gumboro disease, is a viral infection of chickens associated with death at 3-6 weeks of age.
Maltese: IBD, magħrufa wkoll bħala l-marda ta' Gumboro, hija infezzjoni virali tat-tiġieġ assoċjata ma' mewt fl-età ta' 3-6 ġimgħat.
English: Innovax-ND-IBD is a vaccine containing turkey herpesvirus serotype 3, a type of herpesvirus which does not cause disease in chickens but which is similar to the virus that causes MD.
Maltese: Innovax-ND-IBD huwa vaċċin li fih il-virus ħerpes tad-dundjan tas-serotip 3, tip ta' virus ħerpes li ma jikkawżax mard fit-tiġieġ iżda li huwa simili għall-virus li jikkawża MD.
English: MD is a herpesvirus infection of chickens which can cause paralysis of the wings and legs and causes tumours in various organs.
Maltese: MD hija infezzjoni tal-virus ħerpes tat-tiġieġ li tista' tikkawża paraliżi tal-ġwienaħ u tas-saqajn u tikkawża tumuri f'diversi organi.
English: For IBD, vaccinated birds were challenged at 3, 4, 6 and 8 weeks after vaccination.
Maltese: Għal IBD, l-għasafar imlaqqma ġew sfidati fit-3, fir-4, fis-6 u fit-8 ġimgħa wara t-tilqim.
English: Protection against IBD starts 3 weeks after vaccination and lasts 8 weeks.
Maltese: IBD tibda 3 ġimgħat wara t-tilqim u ddum 8 ġimgħat.
English: What are the risks associated with Innovax-ND-IBD?
Maltese: X'inhuma r-riskji assoċjati ma' Innovax-ND-IBD?
English: Safety studies have shown that the strain is safe for turkeys, however, precautionary measures must be followed to avoid direct or indirect contact between vaccinated chickens and turkeys.
Maltese: Studji dwar is-sigurtà wrew li r-razza hija sigura għad-dundjani, madankollu, għandhom jiġu segwiti miżuri ta' prekawzjoni sabiex jiġi evitat kuntatt dirett jew indirett bejn tiġieġ imlaqqma u dundjani.
English: This will help protect the chickens against ND, IBD and herpesvirus infections like MD.
Maltese: Dan ser jgħin jipproteġi lit-tiġieġ kontra ND, IBD u infezzjonijiet tal-virus ħerpes bħal MD.
English: The vaccine can be given to one-day-old chicks as a single injection under the skin in the neck or directly into 18 - 19-day-old chicken eggs containing embryos (unhatched developing chicks).
Maltese: Il-vaċċin jista' jingħata lil flieles ta' jum bħala injezzjoni waħda taħt il-ġilda fl-għonq jew direttament f'bajd ta' tiġieġ ta' 18- 19-il jum li fih l-embrijuni (flieles li qegħdin jiżviluppaw li għadhom ma faqqsux).
English: Why is Innovax-ND-IBD authorised in the EU?
Maltese: Għalfejn Innovax-ND-IBD huwa awtorizzat fl-UE?
English: Safety information has been included in the summary of product characteristics and the package leaflet for Innovax-ND-IBD, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Maltese: Fis-sommarju tal-karatteristiċi tal-prodott u l-fuljett ta' tagħrif ġiet inkluża informazzjoni rigward is-sigurtà ta' Innovax-ND-IBD, inkluż il-prekawzjonijiet xierqa li għandhom ikunu segwiti mill-professjonisti fil-qasam tal-kura tas-saħħa u mis-sidien tal-annimali jew dawk li jieħdu ħsiebhom.
English: How is Innovax-ND-IBD used?
Maltese: Kif jaħdem Innovax-ND-IBD?
English: Innovax-ND-IBD is available as a suspension and solvent to be made into a suspension for injection and can only be obtained with a prescription.
Maltese: Innovax-ND-IBD jiġi bħala sospensjoni u solvent biex jiġu magħmulin f'sospensjoni għall-injezzjoni u jista' jinkiseb biss b'riċetta ta' tabib.
English: Protection against MD starts 9 days after vaccination and lasts for life.
Maltese: MD tibda 9 ijiem wara t-tilqim u ddum tul ħajjithom kollha.